The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTs
NCT06431451 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2025-02-26
Summary
This is a prospective, single-center, observational study to explore the correlation between ripretinib exposure and the efficacy and safety in patients with advanced gastrointestinal stromal tumors
Conditions
Sponsors & Collaborators
-
First Affiliated Hospital, Sun Yat-Sen University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-06-01
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
NCT06104241 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer
NCT05635149 ·Status: UNKNOWN
-
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
NCT06617052 ·Status: NOT_YET_RECRUITING
-
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
NCT05962502 ·Status: RECRUITING ·Phase: PHASE2
-
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
NCT05385549 ·Status: RECRUITING ·Phase: PHASE2
-
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
NCT04835324 ·Status: UNKNOWN
-
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01271582 ·Status: UNKNOWN ·Phase: PHASE4
-
The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer
NCT02425930 ·Status: COMPLETED
-
A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
NCT05731336 ·Status: RECRUITING
-
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
NCT06364371 ·Status: RECRUITING
-
Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
NCT06719414 ·Status: RECRUITING
-
Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-
NCT06895577 ·Status: WITHDRAWN ·Phase: PHASE2
-
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
NCT05148767 ·Status: RECRUITING ·Phase: PHASE4
-
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
NCT06210971 ·Status: RECRUITING ·Phase: PHASE2
-
Salvage Surgery for Patients With Metastatic GIST With Rego
NCT04343456 ·Status: COMPLETED
-
Observational Registry Data on GIST Patients
NCT03602092 ·Status: RECRUITING
-
Gasless Single-port Laparoscopic-assisted Radical Resection for Rectal Carcinoma
NCT03318185 ·Status: UNKNOWN ·Phase: NA
-
Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma
NCT06364384 ·Status: RECRUITING ·Phase: PHASE2
-
BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors
NCT06152757 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
NCT02606097 ·Status: COMPLETED ·Phase: PHASE2
-
Predicting Gastric Cancer Response to Chemo With Multimodal AI Model
NCT06451393 ·Status: RECRUITING
-
Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
NCT04643041 ·Status: RECRUITING ·Phase: NA
-
BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies
NCT06645301 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
An Observational Study of Perioperative Immunotherapy in MSI-H Gastrointestinal Tumors
NCT04640103 ·Status: UNKNOWN
-
Establishment of Individualized Immunotherapy Strategy and Platform Based on Changes of Intestinal Microbiota
NCT05065515 ·Status: UNKNOWN